Cargando…

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?

The approval of immune-checkpoint inhibitors (CPI) and mitogen activated protein kinase inhibitors (MAPKi) in recent years significantly improved the treatment management and survival of patients with advanced malignant melanoma. CPI aim to counter-act receptor-mediated inhibitory effects of tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haist, Maximilian, Stege, Henner, Kuske, Michael, Bauer, Julia, Klumpp, Annika, Grabbe, Stephan, Bros, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348973/ https://www.ncbi.nlm.nih.gov/pubmed/37022618 http://dx.doi.org/10.1007/s10555-023-10097-z

Ejemplares similares

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
por: Kuske, Michael, et al.
Publicado: (2022)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
por: Haist, Maximilian, et al.
Publicado: (2021)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2021)

β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease
por: Bednarczyk, Monika, et al.
Publicado: (2020)

Neutrophil-Specific Knockdown of β2 Integrins Impairs Antifungal Effector Functions and Aggravates the Course of Invasive Pulmonal Aspergillosis
por: Haist, Maximilian, et al.
Publicado: (2022)

Nanodrugs Targeting T Cells in Tumor Therapy
por: Haist, Maximilian, et al.
Publicado: (2022)

Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells
por: Bednarczyk, Monika, et al.
Publicado: (2021)

Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
por: Kuske, Marvin, et al.
Publicado: (2018)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study
por: Mayer, Arnulf, et al.
Publicado: (2020)

Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells
por: Zeyn, Yanira, et al.
Publicado: (2022)

β2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis
por: Bednarczyk, Monika, et al.
Publicado: (2022)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
por: Kalaora, Shelly, et al.
Publicado: (2020)

Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
por: Hieber, Christoph, et al.
Publicado: (2023)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
por: Rieth, John M., et al.
Publicado: (2021)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Interleukin-1 Beta—A Friend or Foe in Malignancies?
por: Bent, Rebekka, et al.
Publicado: (2018)

RhoA as a Key Regulator of Innate and Adaptive Immunity
por: Bros, Matthias, et al.
Publicado: (2019)

Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy
por: Pohl, Julia, et al.
Publicado: (2022)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
por: Ettl, Tobias, et al.
Publicado: (2022)

Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
por: Hirshoren, Nir, et al.
Publicado: (2020)

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma
por: Gondois-Rey, Françoise, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma
por: Wu, Minliang, et al.
Publicado: (2019)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h54vj5pdp15avsot5sks5pkkt2